Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aminolevulinic acid - Nobelpharma/SBI Pharmaceuticals

Next Previous
X
Search
Drug Profile

Aminolevulinic acid - Nobelpharma/SBI Pharmaceuticals

Alternative Names: 5-ALA - Nobelpharma; Alabel; Alaglio; NPC-07; PD G 506 A

Latest Information Update: 09 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SBI Pharmaceuticals Co Ltd
  • Developer Chugai Pharmaceutical; Kyoto University; Nobelpharma; SBI Pharmaceuticals Co Ltd
  • Class Amino acids; Antianaemics; Antineoplastics; Diagnostic agents; Imaging agents; Keto acids; Levulinic acids; Nootropics; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Antioxidants; Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bladder cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glioma
  • Registered Bladder cancer
  • Phase III Breast cancer
  • Phase II Biliary cancer; Pancreatic cancer; Solid tumours
  • No development reported Anaemia; Atherosclerosis; Cervical intraepithelial neoplasia; Cholangiocarcinoma; Cognition disorders

Most Recent Events

  • 01 Oct 2024 Nobelpharma transfers the marketing approval of Alabel® to SBI Pharmaceuticals in Japan
  • 28 Dec 2021 No recent reports of development identified for preclinical development in Atherosclerosis in Japan
  • 28 May 2021 No recent reports of development identified for clinical-Phase-Unknown development in Cervical-intraepithelial-neoplasia(Diagnosis, In adults) in Japan (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top